Business Context and Reporting Period
Company: Amgen Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2006
Business Overview: Amgen is a global biotechnology company discovering, developing, manufacturing, and marketing human therapeutics. Principal products include Aranesp, EPOGEN, Neulasta/NEUPOGEN, and Enbrel. The company operates in a single business segment: human therapeutics.
Key Financial Metrics
| Metric (in millions) | Q1 2006 | Q1 2005 |
|---|---|---|
| Total Revenues | $3,217 | $2,833 |
| Product Sales | $3,127 | $2,735 |
| Operating Income | $1,234 | $1,156 |
| Net Income | $1,001 | $854 |
| Diluted EPS | $0.82 | $0.67 |
| Operating Cash Flow | $1,183 | $1,123 |
| Cash & Equivalents (End of Period) | $1,747 | $1,183 |
| Total Debt (Current + Non-Current) | $8,961 | $3,957 |
Note: Total debt increased significantly in Q1 2006 due to the issuance of $5.0 billion in convertible notes in February 2006.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 14% to $3.2 billion, driven primarily by product sales growth of 14% ($3.1 billion). Key drivers included Aranesp (up 24%), Neulasta/NEUPOGEN (up 13%), and Enbrel (up 11%).
- Expense Increases: Operating expenses rose 18% to $1.98 billion.
- R&D: Increased 25% to $655 million due to higher staff costs, clinical trial funding, and the adoption of SFAS No. 123(R) which added $29 million in stock option expense.
- SG&A: Increased 19% to $689 million, driven by higher staffing levels, legal costs, and marketing expenses, including $37 million in stock option expense.
- Accounting Change: Effective January 1, 2006, Amgen adopted SFAS No. 123(R), requiring the expensing of stock-based compensation. This reduced net income by $45 million and diluted EPS by $0.04 compared to prior accounting methods.
- Financing Activity: Issued $5.0 billion in convertible notes (2011 and 2013 maturities) and sold warrants for $774 million. Concurrently, repurchased $3.0 billion of common stock and purchased $1.5 billion in convertible note hedges.
Guidance, Outlook, and Risks
- Outlook: Management expects Aranesp, Enbrel, and Neulasta to continue driving sales growth in 2006, though share gains may be more challenging than in previous years due to competition. R&D expenses are expected to accelerate in 2006 due to large-scale clinical trials for denosumab.
- Reimbursement Risks: Sales are heavily dependent on government and private payer reimbursement. Changes in Medicare Part B and Part D policies (MMA) and the "Claims Monitoring Policy" for EPOGEN/Aranesp could impact utilization and pricing. The company believes the impact in 2006 will not be significant but remains uncertain.
- Acquisition: Completed the acquisition of Abgenix, Inc. on April 1, 2006, for approximately $2.1 billion in cash plus assumption of debt. This provides full ownership of panitumumab and eliminates tiered royalties on denosumab.
- Legal & IP: Ongoing litigation regarding Average Wholesale Price (AWP) reporting and patent disputes (e.g., with Roche regarding peg-EPO) pose risks. European patent expirations for erythropoietin and G-CSF may lead to biosimilar competition starting in 2007.
- Manufacturing: Significant reliance on the Puerto Rico facility for formulation, fill, and finish of key products creates supply risk in the event of natural disasters or production failures.
Investor Verification Checklist
- Stock-Based Compensation Impact: Verify the full-year impact of SFAS No. 123(R) adoption on margins and EPS, estimated at $0.12 to $0.14 per share for 2006.
- Reimbursement Policy Changes: Monitor CMS updates regarding the Medicare Modernization Act (MMA), specifically the ASP+6% methodology and the Competitive Acquisition Program (CAP), for potential revenue headwinds.
- Abgenix Integration: Track the regulatory approval and commercial launch of panitumumab and the integration of Abgenix's manufacturing capabilities.
- Debt Structure: Review the terms of the new $5.0 billion convertible notes and the associated warrant transactions, noting the potential for future dilution upon conversion.
- Product Mix Shifts: Monitor the conversion rate of EPOGEN users to Aranesp in hospital dialysis clinics, which is expected to stabilize by mid-2006.